MEDVi

MEDVi has rapidly become one of the most talked-about GLP-1 telehealth platforms in the United States, having grown from zero to $401 million in revenue in its first year of operation. The platform was built using AI infrastructure and medical services outsourced through CareValidate and OpenLoop Health networks. MEDVi offers compounded semaglutide and tirzepatide starting at $179/month with no membership fees, no contracts, and no hidden costs — what you see is what you pay. Every subscription includes a physician review of your health intake, a prescription for compounded semaglutide or tirzepatide if clinically appropriate, monthly medication shipments, and 24/7 access to the provider support portal. MEDVi also offers brand-name Ozempic at $1,999/month for patients who prefer the FDA-approved version. The platform has faced scrutiny alongside the broader compounded GLP-1 market following FDA warning letters issued in March 2026, though MEDVi has maintained it operates within compliant frameworks. No membership fee structure makes it one of the cheapest entry points in the market.